{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-23-039183","form_type":"8-K","ticker":"ENVB","cik":"0000890821","company_name":"Enveric Biosciences, Inc.","filed_at":"2023-11-02T23:59:59+00:00","discovered_at":"2026-05-14T18:03:32.300972+00:00","generated_at":"2026-06-09T01:28:56.456345+00:00","sec_items":["5.02","5.07","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Enveric stockholders approve amended 2020 LTIP and share issuance to Lincoln Park Capital","bullets":["Stockholders approved amendment to 2020 LTIP, increasing authorized shares by 38,259 to 350,000.","Amendments remove evergreen auto-increase provision and add one-year minimum vesting.","Issuance of common stock to Lincoln Park Capital Fund approved under Nasdaq Listing Rules 5635(a), (b), (d).","All five director nominees elected; say-on-pay and ratification of Marcum LLP as auditor passed.","Annual meeting turnout: 1,074,661 shares (49.3% of outstanding) constituted quorum."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-23-039183","json":"https://secwatch.observer/filing/0001493152-23-039183.json","markdown":"https://secwatch.observer/filing/0001493152-23-039183.md","text":"https://secwatch.observer/filing/0001493152-23-039183.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/890821/000149315223039183/0001493152-23-039183-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/890821/000149315223039183/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-09T01:28:56.456345+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"3d4948c7784b96ca180511891254f57819fdfadf","claim":"Enveric Biosciences, Inc. shareholders approved Non-binding advisory vote to approve the compensation of the Company's named executive officers, as disclosed in the Proxy Statement. at the 2023-11-02 meeting.","evidence_excerpt":"Non-binding advisory vote to approve the compensation of the Company's named executive officers, as disclosed in the Proxy Statement.","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/890821/000149315223039183/0001493152-23-039183-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"say on pay"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2023-11-02"}],"fact_type":"shareholder_vote"},{"claim_id":"6e337f047726afad778817fd83f1bdd6103451af","claim":"Enveric Biosciences, Inc. shareholders approved Approval of proposed amendments to the Enveric Biosciences, Inc. 2020 Long-Term Incentive Plan, as amended. at the 2023-11-02 meeting.","evidence_excerpt":"Approval of proposed amendments to the Enveric Biosciences, Inc. 2020 Long-Term Incentive Plan, as amended.","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/890821/000149315223039183/0001493152-23-039183-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"equity plan"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2023-11-02"}],"fact_type":"shareholder_vote"},{"claim_id":"82359a0200ff1b60aad8c7fd599c7281a9be5a6e","claim":"Enveric Biosciences, Inc. shareholders approved Ratification of the appointment of Marcum LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2023. at the 2023-11-02 meeting.","evidence_excerpt":"Ratification of the appointment of Marcum LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2023.","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/890821/000149315223039183/0001493152-23-039183-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"auditor ratification"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2023-11-02"}],"fact_type":"shareholder_vote"},{"claim_id":"c5214232600a8849a3162628a9dfe3fcf41634df","claim":"Enveric Biosciences, Inc. shareholders approved Approval of the issuance of shares of common stock to Lincoln Park Capital Fund, LLC pursuant to Nasdaq Listing Rules 5635(a), 5635(b) and 5635(d). at the 2023-11-02 meeting.","evidence_excerpt":"Approval of the issuance of shares of common stock to Lincoln Park Capital Fund, LLC pursuant to Nasdaq Listing Rules 5635(a), 5635(b) and 5635(d).","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/890821/000149315223039183/0001493152-23-039183-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2023-11-02"}],"fact_type":"shareholder_vote"},{"claim_id":"f0fe943c684d429d9b48aa526bd576f7b697e063","claim":"Enveric Biosciences, Inc. shareholders approved Election of five directors, to serve until the Company's 2024 annual meeting of stockholders or until their successors are duly elected and qualified. at the 2023-11-02 meeting.","evidence_excerpt":"On November 2, 2023, the Company held its 2023 Annual Meeting.","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/890821/000149315223039183/0001493152-23-039183-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"director election"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2023-11-02"}],"fact_type":"shareholder_vote"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}